(MEDCL) Medincell - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 934m EUR | Total Return: 71.5% in 12m
Avg Turnover: 2.68M
Warnings
Negative Equity with losses - insolvent profile
Share dilution 18.7% YoY
Interest Coverage Ratio -3.5 is critical
Altman Z'' -2.05 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
MedinCell S.A. (MEDCL) is a France-based biopharmaceutical company specializing in the development of long-acting injectable (LAI) medications. The company utilizes its proprietary BEPO technology platform to create sustained-release formulations, currently marketing UZEDY for schizophrenia and bipolar I disorder. Its clinical pipeline includes mdc-TJK in the NDA preparation stage and mdc-CWM in Phase III trials for postoperative pain management.
The company operates a licensing-heavy business model, partnering with major pharmaceutical entities like AbbVie to manage large-scale manufacturing and commercialization. In the biotechnology sector, LAI technologies are increasingly prioritized to improve patient adherence and stabilize drug plasma levels compared to daily oral regimens. For a deeper look into the companys valuation metrics and market position, continue your research on ValueRay.
MedinCell’s diverse research portfolio extends into preclinical candidates for global health initiatives, including contraception and malaria prevention. Strategic collaborations with organizations such as IM4TB further expand the application of its technology into infectious diseases like tuberculosis.
- UZEDY sales growth and royalty revenue drive near-term cash flow generation
- FDA approval of mdc-TJK for schizophrenia acts as major valuation catalyst
- Phase III clinical trial results for mdc-CWM determine orthopedic market expansion
- AbbVie strategic collaboration milestones provide non-dilutive funding and R&D validation
- BEPO technology platform adoption increases long-term licensing and royalty potential
| Net Income: -51.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA 10.83 > 1.0 |
| NWC/Revenue: 97.82% < 20% (prev 141.6%; Δ -43.83% < -1%) |
| CFO/TA 0.06 > 3% & CFO 4.30m > Net Income -51.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.1m) vs 12m ago 18.73% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 65.43% > 50% (prev 27.37%; Δ 38.06% > 0%) |
| Interest Coverage Ratio: -3.52 > 6 (EBITDA TTM -37.5m / Interest Expense TTM 11.6m) |
| A: 0.54 (Total Current Assets 61.4m - Total Current Liabilities 21.3m) / Total Assets 74.6m |
| B: -0.22 (Retained Earnings -16.1m / Total Assets 74.6m) |
| C: -0.65 (EBIT TTM -40.9m / Avg Total Assets 62.5m) |
| D: -0.44 (Book Value of Equity -46.8m / Total Liabilities 105.2m) |
| Altman-Z'' = -2.05 = D |
| DSRI: 1.07 (Receivables 6.87m/2.17m, Revenue 40.9m/13.8m) |
| GMI: 0.75 (GM 97.18% / 72.62%) |
| AQI: 1.06 (AQ_t 0.11 / AQ_t-1 0.11) |
| SGI: 2.96 (Revenue 40.9m / 13.8m) |
| TATA: -0.75 (NI -51.4m - CFO 4.30m) / TA 74.6m) |
| Beneish M = -2.52 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at EUR 26.62 with a total of 63,159 shares traded.
Over the past week, the price has changed by -0.73%,
over one month by +12.87%,
over three months by +10.13% and
over the past year by +71.48%.
Medincell has no consensus analysts rating.
P/S = 29.6428
P/B = 27.5888
Revenue TTM = 40.9m EUR
EBIT TTM = -40.9m EUR
EBITDA TTM = -37.5m EUR
Long Term Debt = 50.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.62m EUR (from shortTermDebt, last quarter)
Debt = 60.7m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.46m
Net Debt = 33.1m EUR (calculated: Debt 60.7m - CCE 27.6m)
Enterprise Value = 967.4m EUR (934.3m + Debt 60.7m - CCE 27.6m)
Interest Coverage Ratio = -3.52 (Ebit TTM -40.9m / Interest Expense TTM 11.6m)
EV/FCF = -21.86x (Enterprise Value 967.4m / FCF TTM -44.3m)
FCF Yield = -4.58% (FCF TTM -44.3m / Enterprise Value 967.4m)
FCF Margin = -108.2% (FCF TTM -44.3m / Revenue TTM 40.9m)
Net Margin = -125.6% (Net Income TTM -51.4m / Revenue TTM 40.9m)
Gross Margin = unknown ((Revenue TTM 40.9m - Cost of Revenue TTM 1.15m) / Revenue TTM)
Tobins Q-Ratio = 12.97 (Enterprise Value 967.4m / Total Assets 74.6m)
Interest Expense / Debt = 19.14% (Interest Expense 11.6m / Debt 60.7m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -30.7m (EBIT -40.9m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.45 (Total Current Assets 61.4m / Total Current Liabilities 25.0m)
Debt / Equity = -1.98 (negative equity) (Debt 60.7m / totalStockholderEquity, last quarter -30.6m)
Debt / EBITDA = -0.88 (negative EBITDA) (Net Debt 33.1m / EBITDA -37.5m)
Debt / FCF = -0.75 (negative FCF - burning cash) (Net Debt 33.1m / FCF TTM -44.3m)
Total Stockholder Equity = -35.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -82.19% (Net Income -51.4m / Total Assets 74.6m)
RoE = 265.1% (negative equity) (Net Income TTM -51.4m / Total Stockholder Equity -19.4m)
RoCE = -130.1% (out of range, set to none) (EBIT -40.9m / Capital Employed (Equity -19.4m + L.T.Debt 50.8m))
RoIC = -98.25% (negative operating profit) (NOPAT -30.7m / Invested Capital 31.2m)
WACC = 7.47% (E(934.3m)/V(995.0m) * Re(7.02%) + D(60.7m)/V(995.0m) * Rd(19.14%) * (1-Tc(0.25)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 13.41%
[DCF] Fair Price = unknown (Cash Flow -44.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.14 | # QB: 0
Revenue Correlation: 96.02 | Revenue CAGR: 74.81% | SUE: 1.33 | # QB: 3